Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04414189 · ClinicalTrials.gov registry record

Clinical Validation of HostDx Sepsis™ on NanoString; a Prospective Observational Validation Trial

A clinical trial of Sepsis, sponsored by Inflammatix.

Completed
Registry status
200
Enrollment target
1
Study location

NCT04414189 is a study of Sepsis that has completed, run by Inflammatix. The registered enrollment target is 200 participants, below the 6,562-participant average among 90 other Sepsis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04414189, a study of Sepsis, has completed, sponsored by Inflammatix.

COMPLETED
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

This study will analyze HostDx Sepsis results from whole blood samples collected from patients with suspected sepsis or at risk for sepsis in the surgical ICU

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST HostDx Sepsis

Study Locations (1)

Florida

  • University of Florida College of Medicine - Gainesville

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2020-06-07
Est. Completion 2021-10-19

Sponsor

Inflammatix

5 total trials

What the Registry Record Tells You About NCT04414189

The ClinicalTrials.gov registry entry for NCT04414189 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,562-participant average among 90 other Sepsis trials with a reported enrollment target (97% lower). The listed sponsor is Inflammatix, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which HostDx Sepsis is the first listed.

NCT04414189 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT04414189 about?

NCT04414189 is a clinical study titled "Clinical Validation of HostDx Sepsis™ on NanoString; a Prospective Observational Validation Trial". This study will analyze HostDx Sepsis results from whole blood samples collected from patients with suspected sepsis or at risk for sepsis in the surgical ICU

What is the current status of trial NCT04414189?

This trial is currently completed. The enrollment target is 200 participants. The study started on 2020-06-07. Estimated completion is 2021-10-19.

What conditions does trial NCT04414189 study?

This clinical trial studies the following conditions: Sepsis.

What interventions are being tested in trial NCT04414189?

The interventions under investigation include: HostDx Sepsis (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04414189?

This trial is sponsored by Inflammatix, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04414189 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sepsis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.